US, EU Nods For Gilead's Vemlidy To Enter Saturated Hep B Market

Vemlidy, Gilead Sciences' follow-on to blockbuster hepatitis B product treatment Viread, has this week won approval in the US and been given the green light for approval in Europe – vital steps in Gilead's long term plan to protect its hep B portfolio from generic erosion.

FDA approved background, 3D rendering, blue street sign
Gilead Wins US Approval For Hep B drug Vemlidy • Source: Shutterstock

Gilead Sciences Inc. won approval from the US FDA on Nov. 10 for its second generation hepatitis B drug Vemlidy; the compound will be priced in line with its predecessor drug, Gilead's own Viread, at $997.77 per month on the US market.

Unusually, Vemlidy also gained a positive recommendation from the European Medicines Agency's scientific committee, the CHMP, for use in hepatitis...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip